The current therapeutic approach for ischemic stroke is the use of tissue plasminogen activator (tPA), approved by FDA, however a favorable outcome is incumbent upon early treatment (<4 hours of ischemic onset) and less than 5% of qualifying patients actually receive TPA5. The gene discussed is PLAT; the disease is ischemic stroke.